Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

UNKNOWN 1OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 8Lymphoid 7Breast 7Tumor-Agnostic 5Plasma cell 5Myeloid 5Gynecologic 5CNS 5Gastrointestinal 4Dermatologic 4Sarcoma 2Genitourinary 2Other solid neoplasm 1Other neoplasm 1Head & Neck 1

Conditions

Thyroid Neoplasms 1

Interventions

Cisplatin 416Radiotherapy 240Radiotherapy, Intensity-Modulated 178Cetuximab 177Docetaxel 166pembrolizumab 148Carboplatin 121Fluorouracil 113Paclitaxel 90Nivolumab 82Gemcitabine 82Radiation 72Surveys and Questionnaires 71Drug Therapy 70toripalimab 68Surgical Procedures, Operative 64Magnetic Resonance Spectroscopy 63Capecitabine 50Blood Specimen Collection 50Chemoradiotherapy 46Biopsy 44camrelizumab 41durvalumab 40Radiosurgery 40Standard of Care 38Erlotinib Hydrochloride 34nimotuzumab 32130-nm albumin-bound paclitaxel 32tislelizumab 31apatinib 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Ondansetron × Head & Neck × Clear all
NCT06697782 2025-01-22

Aprepitant and Ondansetron Monotherapy or Combination for Postoperative Nausea and Vomiting in Thyroid Cancer

The First Affiliated Hospital of Zhengzhou University

Phase 4 Completed
600 enrolled
Head & Neck

Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡